Diagnosing diseases is basically the frontlines when it comes to fighting against illnesses and how effectively and efficiently this is done will affect how the rest of the battle goes. Unfortunately, diagnosis can be expensive, depending on the disease. Thanks to a new microchip, which can cost only $0.1 to create, this might not be a problem anymore.
The microchip in question was created by a team of engineers from Stanford who published their findings in the Proceedings of the National Academy of Sciences. Not only is the chip tiny, it’s also incredibly inexpensive to produce and can be manufactured at a large scale in a very short period of time.
“For the developing world, point-of-care (POC) diagnostics design must account for limited funds, modest public health infrastructure, and low power availability,” the paper reads. “To address these challenges, here we integrate microfluidics, electronics, and inkjet printing to build an ultra–low-cost, rapid, and miniaturized lab-on-a-chip (LOC) platform.”
Calling it the FNIP chip, the researchers created the device with three layers of varying expendability. As for how it is used, it’s basically a two-step process. First, the user would need to customize the configuration in order to suit the particular disease that needs to be diagnosed, Futurism reports. Next, the necessary samples for analysis can then be printed onto the top layer of the chip.
So, which diseases can this microchip detect? So far, the researchers tested it to analyze cancer fluid and succeeded. They also used it to diagnose immune cells and was able to pull off similar results as another diagnostic tool that would have cost $100,000 in comparison.
Before anyone gets too excited, however, the researchers are saying that it would take some time before the microchip becomes widely available. There are some hurdles to overcome first, including more tests to see if the platform is even safe to use.


FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Coupang Apologizes After Massive Data Breach Affecting 33.7 Million Users
Australia Releases New National AI Plan, Opts for Existing Laws to Manage Risks
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Nexperia Urges China Division to Resume Chip Production as Supply Risks Mount
Apple Alerts EU Regulators That Apple Ads and Maps Meet DMA Gatekeeper Thresholds
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 



